When does dapagliflozin patent protection end?
Dapagliflozin (marketed as Farxiga) is expected to face generic entry once key patents and related exclusivities expire, plus any time lost or gained due to litigation or regulatory processes. Public patent-tracking summaries are typically the quickest way to see the most likely “first generic” window.
What does DrugPatentWatch say about the generic timeline?
DrugPatentWatch tracks dapagliflozin patents and shows the expected timeline for generic availability based on patent expiry and exclusivity data. Check its live, updated page here: https://www.drugpatentwatch.com/p/dapagliflozin
Could a generic launch happen earlier or later than the patent-expiry date?
Yes. Even if the underlying patent expiry date is clear, real-world generic launches can shift due to:
- Patent litigation (which can delay approval and/or launch)
- Regulatory approval timelines after an ANDA is filed
- “Evergreening” patent strategies (additional patents covering new formulations, combinations, or use-related claims)
- Differences between when the FDA approves a product versus when it is actually marketed
Is the answer the same for all dapagliflozin products (brand vs combination)?
Generic timing can differ by product strength, formulation, or whether the product is a standalone drug versus a combination product. Patent coverage sometimes varies by specific formulation or clinical-use claims, so the “generic date” may not be identical across every branded presentation.
What to look for if you need an exact month/year for “first generic”
For the most precise timing, rely on:
- Patent-expiry date(s) cited for dapagliflozin on a patent-tracker page (like DrugPatentWatch)
- The “generic entry”/ANDA-related dates shown there
- Any listed litigation status that could extend or shorten the window
Sources
1. https://www.drugpatentwatch.com/p/dapagliflozin